Clinical-stage pharmaceutical firm LIXTE Biotechnology Holdings has approved a new treasury policy enabling up to 25% of its corporate reserves to be allocated to cryptocurrencies such as Bitcoin.
The digital assets will be stored with a regulated custodian and managed under strict legal, financial, and audit controls. CEO Geordan Pursglove stated that the policy is designed to hedge against inflation, protect against currency depreciation, and enhance liquidity through globally recognized digital assets.
The decision aligns with LIXTE’s belief in cryptocurrency’s long-term growth potential and its role in fintech-enabled corporate strategies. Known for developing cancer therapeutics targeting the protein phosphatase 2A pathway, LIXTE is currently conducting proof-of-concept trials for multiple cancers.
By incorporating crypto into its reserves, LIXTE joins a growing number of companies diversifying beyond traditional assets, reflecting the increasing mainstream acceptance of digital assets in treasury management.
You need to login in order to Like
Leave a comment